A randomized, double-blind controlled trial for sanzihuangshi pill in the treatment of relatively low-risk myelodysplastic syndromes

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000037413

Enrollment

Unknown

Registered

2020-08-28

Start date

2021-02-01

Completion date

Unknown

Last updated

2020-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myelodysplastic syndrome

Interventions

Experimental group:sanzihuangshi pill

control group:The placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Aged 18-75 years old; 2) Meet MDS diagnostic criteria for low and medium risk I in western medicine; 3) It meets the diagnostic criteria of TCM syndromes and is determined by the syndrome differentiation of two senior TCM hematopathy experts;

Exclusion criteria

Exclusion criteria: 1) Secondary MDS; 2) Patients with other blood or non-blood system tumors; 3) Patients with more serious organic diseases such as heart, liver and kidney; 4) Patients during pregnancy or lactation; 5) People with mental illness; 6) Patients with Class A and B infectious diseases; 7) 5q - Patients

Design outcomes

Primary

Measure	Time frame
blood routine test;	—

Countries

China

Contacts

Public ContactJianye Ren

Shanghai Municipal Hospital of Traditional Chinese Medicine

578389997@qq.com+86 13816948569

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026